Zenosense

Zenosense is rated 3 out of 5 in the category medical devices. Read and write reviews about Zenosense. The Revolution in Cardiac Diagnostics Zenosense, Inc. (OTCQB:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialization of MIDS Cardiac™, a hand held device being developed for the rapid testing of cardiac markers to deliver rapid results equal or superior to laboratory gold standard accuracy at the Point of Care. MIDS Cardiac is aimed at revolutionizing the diagnosis and management of suspected Acute Myocardial Infarction (AMI) by enabling high sensitivity cardiac marker testing at the Point of Care for the first time. The MIDS Medical team has world class expertise and technical know-how of the application of highly specialized, cutting edge nanomagnetic detection technology to diagnostic testing. This knowledge, alongside commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialize MIDS Cardiac and to become a leading innovator in this field. Laboratory The MIDS Medical laboratory is located at the prestigious, UK Government supported Sci-Tech Daresbury campus in the UK. Sci-Tech Daresbury is internationally recognized for leading-edge scientific research and commercial development.